Cancer, Immune Thrombocytopenia, Immune Thrombocytopenic Purpura, Neoplasms
Conditions
Keywords
Proteomics, Mortality, Side Effects, Multicenter, Retrospective
Brief summary
The association between hematologic malignancies and ITP is well described, but this link is much less clear with solid cancers. In cases of ITP associated with cancers, specific cancer treatment can lead to remission or even cure of ITP. Thus, our hypothesis was that chronic expression of GPIIB by tumor cells could have initiated an autoimmune loop against GPIIB, leading to the onset and perpetuation of ITP.
Detailed description
Autoimmune thrombocytopenia, also known as immune thrombocytopenic purpura (ITP), is a rare autoimmune disease characterized by platelet destruction and impaired production, posing a life-threatening risk due to bleeding complications. The pathophysiology of ITP involves complex mechanisms, including both defective platelet production and auto-reactivity of B and T lymphocytes leading to the production of autoantibodies against platelets, found in 35 to 55% of cases. Additionally, in the context of neoplasia, some patients may develop varying degrees of thrombocytopenia, exacerbating morbidity and mortality. A multicenter, retrospective study will collect data from routine care, including birth date, gender, biological parameters related to ITP, dates of treatment initiation and diagnosis of ITP and cancer, types of treatments, and outcomes such as survival or death, without additional medical interventions or appointments.
Interventions
OTHERITP and cancer
ITP and cancer
Sponsors
University Hospital, Bordeaux
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients with a definite diagnosis of both ITP and cancer; * Synchronous diagnosis of ITP and cancer; * Onset of ITP occurring 6 months before or after the diagnosis of cancer.
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission rate of ITP at 6 months after specific cancer treatment | At baseline (Day 0) |
Secondary
| Measure | Time frame |
|---|---|
| All-cause mortality | At baseline (Day 0) |
| Side effects related to ITP and its treatment | At baseline (Day 0) |
| Side effects related to its treatment | At baseline (Day 0) |
| Clinical description of the characteristics of ITP associated with a diagnosis of solid cancer | At baseline (Day 0) |
| Biological description of the characteristics of ITP associated with a diagnosis of solid cancer | At baseline (Day 0) |
| Demographic description of the characteristics of ITP associated with a diagnosis of solid cance | At baseline (Day 0) |
| Therapeutic description of the characteristics of ITP associated with a diagnosis of solid cance | At baseline (Day 0) |
Countries
France
Contacts
PRINCIPAL_INVESTIGATOREtienne RIVIERE, MD
University Hospital, Bordeaux
Outcome results
None listed